SARS-CoV-2 Nucleocapsid 抗体
(11 references)Quick Overview for SARS-CoV-2 Nucleocapsid 抗体 (ABIN6952432)
抗原
See all SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) 抗体适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
特异性
- Specific for the nucleoprotein of the SARS virus.
-
纯化方法
- SARS-CoV-2 (COVID-19, 2019-nCoV) Nucleoprotein antibody is purified from ascites fluid or culture medium by protein A chromoatography or sequential differential precipitations.
-
亚型
- IgG2b
-
-
anti-SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) (Whole Molecule) antibody
Animal-Free SARS-CoV-2 N 适用: SARS Coronavirus-2 (SARS-CoV-2) ELISA, WB, IF, FACS 宿主: 小鼠 Monoclonal AB79-E11 unconjugated Recombinant Antibody
anti-SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) (AA 1-419) antibodySARS-CoV-2 N 适用: SARS Coronavirus-2 (SARS-CoV-2) ELISA, WB, GICA 宿主: HEK-293 Cells Chimeric 1A6 unconjugated scFv fragment Recombinant Antibody
anti-SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) antibodySARS-CoV-2 N 适用: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV) ELISA, IF 宿主: 兔 Chimeric CR3018 (03-018) unconjugated Recombinant Antibody
anti-SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) antibodySARS-CoV-2 N 适用: SARS Coronavirus-2 (SARS-CoV-2) ELISA, WB, IF 宿主: 小鼠 Monoclonal unconjugated
anti-SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) antibodySARS-CoV-2 N 适用: SARS Coronavirus-2 (SARS-CoV-2) ELISA, WB, GICA 宿主: 小鼠 Monoclonal 3C6 unconjugated
anti-SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) (AA 1-419) antibodySARS-CoV-2 N 适用: SARS Coronavirus-2 (SARS-CoV-2) ELISA, GICA 宿主: Human Chimeric 1A6 unconjugated scFv fragment Recombinant Antibody
anti-SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) (AA 1-419) antibodySARS-CoV-2 N 适用: SARS Coronavirus-2 (SARS-CoV-2), Virus ELISA, WB 宿主: 兔 Polyclonal unconjugated
anti-SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) (AA 1-419) antibody (HRP)SARS-CoV-2 N 适用: SARS Coronavirus-2 (SARS-CoV-2) ELISA 宿主: Human Monoclonal 1A6 HRP scFv fragment Recombinant Antibody
anti-SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) (C-Term) antibodySARS-CoV-2 N 适用: SARS Coronavirus-2 (SARS-CoV-2) WB 宿主: 山羊 Polyclonal unconjugated
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
缓冲液
- phosphate saline buffer (0.01M, pH 7.2) containing 0.1 % sodium azide preservative. No stabilizing proteins have been added.
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- -20 °C
-
储存方法
- antibody can be stored at -20°C, stable for one year.
-
有效期
- 12 months
-
-
-
: "Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection." in: PloS one, Vol. 18, Issue 2, pp. e0281281, (2023) (PubMed).
: "Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 120, Issue 30, pp. e2221809120, (2023) (PubMed).
: "Evaluating the in vitro efficacy of bovine lactoferrin products against SARS-CoV-2 variants of concern." in: Journal of dairy science, (2022) (PubMed).
: "Identification of cell type specific ACE2 modifiers by CRISPR screening." in: PLoS pathogens, Vol. 18, Issue 3, pp. e1010377, (2022) (PubMed).
: "ARF6 is an important host factor for SARS-CoV-2 infection in vitro." in: bioRxiv : the preprint server for biology, (2022) (PubMed).
: "In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment." in: bioRxiv : the preprint server for biology, (2022) (PubMed).
: "Surface translocation of ACE2 and TMPRSS2 upon TLR4/7/8 activation is required for SARS-CoV-2 infection in circulating monocytes." in: Cell discovery, Vol. 8, Issue 1, pp. 89, (2022) (PubMed).
: "In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment." in: Vaccines, Vol. 10, Issue 8, (2022) (PubMed).
: "Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Issue 36, (2021) (PubMed).
: "Prolonged SARS-CoV-2 replication in an immunocompromised patient." in: The Journal of infectious diseases, (2020) (PubMed).
: "Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19." in: bioRxiv : the preprint server for biology, (2020) (PubMed).
-
: "Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection." in: PloS one, Vol. 18, Issue 2, pp. e0281281, (2023) (PubMed).
-
- SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)
-
别名
- SARS-CoV-2 Nucleocapsid Protein
-
物质类
- Viral Protein
抗原
-
